Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection

References

• Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988; 11(Suppl. A)411–426
   PubMedGoogle Scholar
• Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–574
   PubMed Web of Science ®Google Scholar
• Mok WY, Barreto da Silva MS. Mycoflora of the human dermal surfaces. Can J Microbiol 1984; 30: 1205–1209
   PubMed Web of Science ®Google Scholar
• Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22(Suppl. 2)S112–S118
   PubMed Web of Science ®Google Scholar
• Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138–1147
   PubMed Web of Science ®Google Scholar
• Silveira F, Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis 2001; 14: 679–684
   PubMed Web of Science ®Google Scholar
• Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother 2003; 15(Suppl. 2)36–47
   PubMedGoogle Scholar
• Perfect JR, Schell WA, Cox GM. Phaeohyphomycoses. Medical Mycology, KJ Kwon-Chung, JE Bennett. Lea & Febiger, Philadelphia 1992; 271–282
   Google Scholar
• Nucci M, Akiti T, Barreiros G, et al. Nosocomial outbreak of Exophiala jeanselmei fungemia associated with contamination of hospital water. Clin Infect Dis 2002; 34: 1475–1480
   PubMed Web of Science ®Google Scholar
• Nucci M, Akiti T, Barreiros G, et al. Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infections. J Clin Microbiol 2001; 39: 514–518
   PubMed Web of Science ®Google Scholar
• Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38: 206–216
   PubMed Web of Science ®Google Scholar
• Revankar SG, Patterson JE, Sutton DA, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34: 467–476
   PubMed Web of Science ®Google Scholar
• Rinaldi MG. Phaeohyphomycosis. Dermatol Clin 1996; 14: 147–153
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS document M27-A2. Wayne, PA: NCCLS; 2002.
   Google Scholar
• González GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45: 1854–1859
   PubMed Web of Science ®Google Scholar
• Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2339–2344
   PubMed Web of Science ®Google Scholar
• Sugar AM, Liu X. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40: 1314–1316
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–1131
   PubMed Web of Science ®Google Scholar
• Negroni R, Helou SH, Petri N, et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004; 38: e15–e20
   Web of Science ®Google Scholar
• Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835–1836
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Trinh JV, Steinbach WJ, Schell WA, et al. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol 2003; 41: 339–345
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009–2015
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Johnson E, et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004; 48: 2288–2291
   PubMed Web of Science ®Google Scholar